These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 26332554)

  • 1. Type 2 Diabetes, SGLT2 Inhibitors, and Glucose Secretion.
    Hattersley AT; Thorens B
    N Engl J Med; 2015 Sep; 373(10):974-6. PubMed ID: 26332554
    [No Abstract]   [Full Text] [Related]  

  • 2. SGLT1 in pancreatic α cells regulates glucagon secretion in mice, possibly explaining the distinct effects of SGLT2 inhibitors on plasma glucagon levels.
    Suga T; Kikuchi O; Kobayashi M; Matsui S; Yokota-Hashimoto H; Wada E; Kohno D; Sasaki T; Takeuchi K; Kakizaki S; Yamada M; Kitamura T
    Mol Metab; 2019 Jan; 19():1-12. PubMed ID: 30416006
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells.
    Solini A; Sebastiani G; Nigi L; Santini E; Rossi C; Dotta F
    Diabetes Metab; 2017 Dec; 43(6):512-520. PubMed ID: 28499695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dapagliflozin suppresses glucagon signaling in rodent models of diabetes.
    Wang MY; Yu X; Lee Y; McCorkle SK; Chen S; Li J; Wang ZV; Davidson JA; Scherer PE; Holland WL; Unger RH; Roth MG
    Proc Natl Acad Sci U S A; 2017 Jun; 114(25):6611-6616. PubMed ID: 28584109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion.
    Bonner C; Kerr-Conte J; Gmyr V; Queniat G; Moerman E; Thévenet J; Beaucamps C; Delalleau N; Popescu I; Malaisse WJ; Sener A; Deprez B; Abderrahmani A; Staels B; Pattou F
    Nat Med; 2015 May; 21(5):512-7. PubMed ID: 25894829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 is not expressed in pancreatic α- and β-cells, and its inhibition does not directly affect glucagon and insulin secretion in rodents and humans.
    Chae H; Augustin R; Gatineau E; Mayoux E; Bensellam M; Antoine N; Khattab F; Lai BK; Brusa D; Stierstorfer B; Klein H; Singh B; Ruiz L; Pieper M; Mark M; Herrera PL; Gribble FM; Reimann F; Wojtusciszyn A; Broca C; Rita N; Piemonti L; Gilon P
    Mol Metab; 2020 Dec; 42():101071. PubMed ID: 32896668
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapy: SGLT2 inhibitor dapagliflozin promotes glucagon secretion in α islet cells.
    Sargent J
    Nat Rev Endocrinol; 2015 Jul; 11(7):382. PubMed ID: 25942656
    [No Abstract]   [Full Text] [Related]  

  • 8. Dapagliflozin promotes beta cell regeneration by inducing pancreatic endocrine cell phenotype conversion in type 2 diabetic mice.
    Wei R; Cui X; Feng J; Gu L; Lang S; Wei T; Yang J; Liu J; Le Y; Wang H; Yang K; Hong T
    Metabolism; 2020 Oct; 111():154324. PubMed ID: 32712220
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SGLT2 inhibition and glucagon secretion in humans.
    Saponaro C; Pattou F; Bonner C
    Diabetes Metab; 2018 Nov; 44(5):383-385. PubMed ID: 30017776
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dapagliflozin stimulates glucagon secretion at high glucose: experiments and mathematical simulations of human A-cells.
    Pedersen MG; Ahlstedt I; El Hachmane MF; Göpel SO
    Sci Rep; 2016 Aug; 6():31214. PubMed ID: 27535321
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insulin inhibits glucagon release by SGLT2-induced stimulation of somatostatin secretion.
    Vergari E; Knudsen JG; Ramracheya R; Salehi A; Zhang Q; Adam J; Asterholm IW; Benrick A; Briant LJB; Chibalina MV; Gribble FM; Hamilton A; Hastoy B; Reimann F; Rorsman NJG; Spiliotis II; Tarasov A; Wu Y; Ashcroft FM; Rorsman P
    Nat Commun; 2019 Jan; 10(1):139. PubMed ID: 30635569
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets.
    Saponaro C; Mühlemann M; Acosta-Montalvo A; Piron A; Gmyr V; Delalleau N; Moerman E; Thévenet J; Pasquetti G; Coddeville A; Cnop M; Kerr-Conte J; Staels B; Pattou F; Bonner C
    Diabetes; 2020 May; 69(5):902-914. PubMed ID: 31896553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can the Combination of Incretin Agents and Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors Reconcile the Yin and Yang of Glucagon?
    Goldenberg RM; Verma S; Perkins BA; Gilbert JD; Zinman B
    Can J Diabetes; 2017 Feb; 41(1):6-9. PubMed ID: 27838228
    [No Abstract]   [Full Text] [Related]  

  • 14. SGLT-2 inhibition and glucagon: Cause for alarm?
    Kibbey RG
    Trends Endocrinol Metab; 2015 Jul; 26(7):337-8. PubMed ID: 26059706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition.
    Capozzi ME; Coch RW; Koech J; Astapova II; Wait JB; Encisco SE; Douros JD; El K; Finan B; Sloop KW; Herman MA; D'Alessio DA; Campbell JE
    Diabetes; 2020 May; 69(5):882-892. PubMed ID: 32005706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Research progress of sodium-glucose co-transporter 2 inhibitors for treatment of type 2 diabetes].
    Wan HX; Shen JK
    Yao Xue Xue Bao; 2012 Jun; 47(6):716-24. PubMed ID: 22919717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of renal and cardiovascular protection mechanisms of SGLT2 inhibitors: model-based analysis of clinical data.
    Hallow KM; Greasley PJ; Helmlinger G; Chu L; Heerspink HJ; Boulton DW
    Am J Physiol Renal Physiol; 2018 Nov; 315(5):F1295-F1306. PubMed ID: 30019930
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of sodium-glucose linked cotransporters 1 and 2 exacerbates cardiac dysfunction following experimental myocardial infarction.
    Connelly KA; Zhang Y; Desjardins JF; Thai K; Gilbert RE
    Cardiovasc Diabetol; 2018 Jul; 17(1):99. PubMed ID: 29981571
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sodium-Glucose linked transporter 2 (SGLT2) inhibitors--fighting diabetes from a new perspective.
    Angelopoulos TP; Doupis J
    Adv Ther; 2014 Jun; 31(6):579-91. PubMed ID: 24972995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Shift to Fatty Substrate Utilization in Response to Sodium-Glucose Cotransporter 2 Inhibition in Subjects Without Diabetes and Patients With Type 2 Diabetes.
    Ferrannini E; Baldi S; Frascerra S; Astiarraga B; Heise T; Bizzotto R; Mari A; Pieber TR; Muscelli E
    Diabetes; 2016 May; 65(5):1190-5. PubMed ID: 26861783
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.